替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2022.04.010

摘要/Abstract

摘要： 目的探讨替诺福韦治疗不同HBV基因型感染的慢性乙型肝炎(CHB)患者的疗效和血清金属硫蛋白(MT)、白细胞介素29(IL-29)和外周血淋巴细胞程序性死亡受体-1(PD-1)表达的变化。方法 2017年1月～2020年11月我院诊治的CHB患者119例,均接受替诺福韦治疗。采用ELISA法检测血清MT和IL-29水平,使用流式细胞仪检测外周血T 淋巴细胞PD-1表达水平。结果在本组119例CHB患者中,检出HBV B基因型31例(26.1%),C基因型77例(64.7%),B/C 混合基因型11例(9.2%);基线资料比较,B基因型CHB患者血清ALT和AST水平分别为(154.1±46.7)U/L和(83.3±26.8)U/L,显著高于C基因型患者【分别为(135.8±40.3)U/L和(68.5±20.6)U/L,P＜0.05】或B/C混合基因型患者【分别为(138.9±50.2)U/L和(71.6±23.9)U/L,P＜0.05】,而血清HBV DNA水平为(6.7±1.1)lg copies/ml,显著低于C基因型感染患者【(7.8±1.4)lg copies/ml,P＜0.05】或B/C混合型感染者【(7.4±1.0)lg copies/ml,P＜0.05】;在治疗24 w和48 w末,三组血清ALT复常率无显著性差异(P>0.05),而B基因型和C基因型感染患者血清HBV DNA阴转率分别为96.8%和96.8%,和88.3%和93.5%,均显著高于B/C混合型感染患者(分别为63.6%和81.8%,P<0.05);在治疗48 w,B基因型CHB患者血清MT水平显著高于C基因型或B/C基因型(P＜0.05),血清IL-29水平显著高于C基因型(P＜0.05),而外周血CD4⁺和CD8⁺T淋巴细胞表面PD-1表达水平显著低于C基因型或B/C混合基因型患者(P＜0.05)。结论不同HBV基因型感染的CHB患者可能对替诺福韦治疗的疗效存在差异,深入了解这些差异可能对研究不同基因型病毒感染患者临床转归有帮助。

关键词: 慢性乙型肝炎, HBV基因型, 替诺福韦, 治疗

Abstract: Objective The aim of this study was to investigate the response to tenofovir antiviral therapy in chronic hepatitis B (CHB) patients with different HBV genotype infection. Methods A total of 119 patients with CHB were enrolled in our hospital between January 2017 and November 2020, and all received tenofovir therapy. The HBV genotypes were detected. Serum metallothionein (MT) and interleukin-29 (IL-29) levels were assayed by ELISA. The programmed cell death-1 (PD-1) expression on peripheral blood lymphocytes was detected by FCM. Results Out of the 119 patients with CHB, the HBV genotype B infection was found in 31 cases(26.1%), genotype C infection was found in 77 cases (64.7%) and genotype B/C mixed infection in 11 patients (9.2%); at baseline, serum ALT and AST levels in CHB patients with genotype B infection were (154.1±46.7)U/L and (83.3±26.8)U/L, significantly higher than [(135.8±40.3)U/L and (68.5±20.6)U/L, P＜0.05] in patients with C infection or[(138.9±50.2)U/L and (71.6±23.9)U/L, P＜0.05] in B/C mixed infection, while serum HBV DNA load was (6.7±1.1)lg copies/ml, significantly lower than [(7.8±1.4)lg copies/ml, P＜0.05] in C or[(7.4±1.0)lg copies/ml, P＜0.05] in B/C infection; at the end of 24 week and 48 week treatment, there were no significant differences as respect to serum ALT normalization rates in the three groups (P>0.05), while serum HBV DNA loss in patients with B and C infection were 96.8% and 96.8%, and 88.3% and 93.5%, all significantly higher than 63.6% and 81.8% (P<0.05) in patients with B/C mixed infection; at the end of 48 week treatment, serum MT level in patients with B infection was significantly higher than in patients with C or B/C infection (P＜0.05), serum IL-29 level was significantly higher than in patients with C infection (P＜0.05), while the PD-1 expression on peripheral blood CD4⁺ and CD8⁺T cell surfaces was significantly lower than in patients with C or B/C infection (P＜0.05). Conclusion The antiviral response to tenofovir treatment in CHB patients with different HBV genotype infection could be different, and further investigation on this might help deal with them appropriately in clinical practice and improve the outcomes of them.

Key words: Hepatitis B, HBV genotype, Tenofovir, Therapy

刘雨莹, 张娇珍, 周海娟, 潘芳蝶, 黎才丽, 钟昌宝. 替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 492-495.

Liu Yuying, Zhang Jiaozhen, Zhou Haijuan, et al. Response to tenofovir antiviral therapy different in patients with chronic hepatitis B and different HBV genotype infection?[J]. Journal of Practical Hepatology, 2022, 25(4): 492-495.

参考文献

[1] 朱义玲,甘建和,赵卫峰,等.慢性乙型肝炎患者外周血调节性T细胞、Th17细胞的水平及与乙肝表面抗原滴度的相关性.中国感染与化疗杂志,2020,20(5):493-497.
[2] Abdulkareem LO, Ndububa DA, Uhunmwangho AO,et al. Hepatitis D virus antibodies and liver function profile among patients with chronic hepatitis B infection in Abuja, Nigeria. J Infect Dev Ctries, 2021,15(1):141-146.
[3] Suoh M, Tamori A, Amano-Teranishi Y, et al. Theadministration of tenofovir disoproxil fumarate for pregnant Japanese women with chronic Hepatitis B. Int Med,2020, 59(2):205-210.
[4] Charlton MR, Alam A, Shukla A,et al. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol, 2020,55(9):811-823.
[5] Mokaya J, Maponga TG, McNaughton AL,et al.Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. J Clin Virol, 2020,129(8):1045-1048.
[6] Ma N, Liu W, Zhang X,et al. Oxidative stress-related gene polymorphisms are associated with hepatitis B virus-induced liver disease in the northern Chinese Han population. Front Genet, 2020,8(7):1290-1293.
[7] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年).实用肝脏病杂志,2016,19(3):V-XVI.
[8] 谢知兵,周建亮,于红缨,等.乙型肝炎病毒前基因组RNA检测在乙型肝炎治疗中的临床研究.中华医院感染学杂志,2020,30(5):693-697.
[9] Elgaml A, Elegezy M, El-Mesery M,et al. Natural variability in surface antigen and reverse transcriptase domain of hepatitis B virus in treatment-naïve chronic HBV-infectedEgyptian patients. Virus Res, 2021,30(2):1984-1992.
[10] Ha Y, Chon YE, Kim MN,et al. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep, 2020,10(1):135-137.
[11] Kamal F, Khan MA, Ahmed A,et al. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B. Gut, 2020,69(11):2054-2056.
[12] Elabd NS, Montaser BA, Gohar S, et al. Relation betweeninterleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients.Ann Oncol,2020,30(9):51-53.
[13] Glebe D, Goldmann N, Lauber C,et al. HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. Antiviral Res, 2021,18(6):104-107.
[14] Nyarko E, Obirikorang C, Owiredu WA,et al. NTCP gene polymorphisms and hepatitis B virus infection status in a Ghanaian population.Virol J,2020,17(1):91.
[15] Tan M, Bhadoria AS, Cui F,et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021,6(2):106-119.
[16] Li M, Xu Y, Pu K,et al. Genetic polymorphisms of chemokine (C-X-C motif) ligand 10 gene associated with hepatitis B virus infection in a Chinese Han population.Int Immunopharmacol,2021,98(9):107888.
[17] Yadav VS, Mir RA, Bhatia A,et al. Metallothionein levels in gingival crevicular fluid, saliva, and serum of smokers and non-smokers with chronic periodontitis. J Periodontol, 2021,92(9):1329-1338.
[18] Wu J, Lin S, Liu S,et al. The association between vitamin D-related gene polymorphisms and hepatitis B virus-related liver cirrhosis. J Int Med Res,2020,48(4):3006.
[19] Roberts A, Bentley L, Tang T,et al.Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. Sci Rep,2021,11(1):4030.
[20] Selma W, Laribi AB, Alibi S,et al. Interaction analysis of IL-12A and IL-12B gene variants with chronic hepatitis B infection in Tunisian patients. Immunol Lett, 2020,22(5):50-56.

替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究^*

Response to tenofovir antiviral therapy different in patients with chronic hepatitis B and different HBV genotype infection?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘霖, 胡蕴, 许岚. 糖脂代谢紊乱相关疾病患者生活方式管理现状和研究进展^*[J]. 实用肝脏病杂志, 2022, 25(4): 464-467.
[2]	熊霞鹂, 魏宏, 朱云霞, 段钟平. 富马酸替诺福韦二吡呋酯对HBV感染孕妇肾功能和胎儿生长发育的安全性研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 484-487.
[3]	贾婷, 李俊义, 张秀灵, 高斯媛, 杨婧, 杨晓冬. 恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 488-491.
[4]	徐欢, 王广丽, 董丹丹, 黄荷. 聚乙二醇干扰素α-2a联合利巴韦林标准抗病毒治疗慢性丙型肝炎患者疗效再研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 500-503.
[5]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[6]	季雪纯, 金世柱, Nepal Narayan, 李宁, 杨宁宁, 张思佳, 林秋池, 陈浩源. 高位食管静脉曲张破裂出血患者内镜诊治经验:10年单中心回顾性分析[J]. 实用肝脏病杂志, 2022, 25(4): 530-533.
[7]	汤磊, 彭蕾, 叶珺, 张振华, 邹桂舟. 影响慢性乙型肝炎患者进展为肝硬化的多因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 538-541.
[8]	刘浩, 周菲菲, 孙好凯, 刘永刚. 基于CBCT的三维重建技术用于TACE术治疗原发性肝癌患者对肿瘤供血动脉识别的价值^*[J]. 实用肝脏病杂志, 2022, 25(4): 563-566.
[9]	张静, 林铤, 孙翔. 超声引导下穿刺抽液联合聚桂醇置换冲洗硬化治疗巨大肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 571-574.
[10]	林益坤, 谢朗, 符剑鸣, 崔春晖. 肝部分切除联合胆肠吻合术治疗肝内胆管结石患者临床疗效及术后结石复发危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 591-594.
[11]	黄鹏, 孟凡斌, 张晓农, 于延铭. 3D模型指导下PTCSL微创治疗复杂性肝胆管结石患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 595-598.
[12]	邹吉, 陈晓波, 董仁华, 张浩. 胆囊切除联合肝组织楔形切除和区域淋巴结清扫治疗胆囊癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 599-602.
[13]	魏博文, 任峥, 张亮, 汪伟. 增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析[J]. 实用肝脏病杂志, 2022, 25(4): 603-604.
[14]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[15]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.